abstract: AIM: The aim of the study was to evaluate the prevalence and risk factors of @entity1 among Polish adolescent @entity0 . MATERIAL AND METHODS: A total of 2500 females from the Upper Silesian region of Poland, aged 16 to 45 years, were eligible for a prospective population-based study. The subjects were recruited randomly by the regional public opinion research centre. The preliminary study population consisted of 1540 females. Seventy-two adolescent @entity0 , aged 16 to 19 years, were included in the final analysis. The research was based on a self-prepared questionnaire containing socio-economic status, general health, medical and reproductive history, @entity2 based on American College of Obstetricians and Gynecologists criteria for diagnosing @entity3 as well as American Psychiatric Association criteria for @entity4 and @entity0 prospective daily ratings of symptoms. RESULTS: The mean age of the studied population was 17.27  0.97 years. In the studied population the majority of the adolescent @entity0 lived in large cities of over 50,000 citizens (54.29%), were physically active declaring daily physical exercise (55.22%) and sexually active (54.17%). Study results indicated that the prevalence of @entity3 and @entity4 was 76.39% and 4.17%, respectively. The final statistical analysis revealed that only place of residence (large cities) increased the risk of @entity3 (OR=3.58; P=0.01). CONCLUSION: Adolescent females living in urban areas are more vulnerable to @entity3 . Reproductive, sexual and socio-economic factors are not significant risk factors for @entity3 .

title: @entity1 in Polish adolescent XXXX : prevalence and risk factors.

answer: @entity0


abstract: BACKGROUND: @entity1 ( @entity1 ) has become the procedure of choice in the treatment of @entity2 where a single @entity4 can be localized preoperatively. The role for intra-operative @entity3 measurement (IOPTH) is controversial. Some experts recommend that IOPTH is a mandatory requirement for successful @entity1 while others state that the technique is not needed. We reviewed 10 years of @entity1 in a single unit without the use of IOPTH in order to examine causes of failure. METHODS: This study is a retrospective review of the University of Sydney Endocrine Surgery Database from May of 1998 to August of 2008. The database was queried for MIPs performed as well as for failed operations. @entity0 record analysis was completed to determine the reason for failure of the operation. RESULTS: In the period January 1998 to August 2008, a total of 2343 parathyroidectomy procedures were performed. Of these, 1020 were MIPs with 23 (2.2%) failures. One @entity0 was found to have benign familial @entity6 , whereas five were lost to follow-up. Reasons for failure in the remaining 17 @entity0 were: 10 @entity0 (59%) were found to have double @entity4 , 3 (17%) @entity0 with @entity5 and 4 (24%) @entity0 with single gland disease were missed at initial operation. All 17 were cured on repeat exploration. CONCLUSION: @entity1 can be performed safely and with 98% success without the need for IOPTH. The most common cause of failure after @entity1 is an occult double @entity4 . Given that repeat sestamibi scan correctly identifies persistent disease in most cases, consideration can be given to @entity1 as a choice of procedure for repeat operation.

title: 1000 minimally invasive parathyroidectomies without intra-operative XXXX measurement: lessons learned.

answer: @entity3


abstract: BACKGROUND: Available drug-eluting stents (DES) have achieved great success in reducing restenosis rates. Recently, investigators have demonstrated that the durable polymer carrier plays a significant role in DES-related hypersensitive reaction and delays vessel healing. TIVOLI stent is a novel @entity8 -eluting coronary stent with biodegradable coating containing @entity8 and @entity9 ( @entity9 ) polymer. The present study sought to evaluate the effectiveness and safety of the TIVOLI biodegradable-polymer-based @entity8 -eluting stent in treating @entity0 with @entity5 . METHODS: A prospective, multicenter clinical trial comparing TIVOLI biodegradable coated @entity8 -eluting stent with ENDEAVOR zotarolimus-eluting stent was conducted in 324 @entity0 (TIVOLI group: 168 @entity0 ; ENDEAVOR group: 156 @entity0 ) at 12 centers in China to demonstrate the non-inferiority of in-stent late loss with TIVOLI stent compared to ENDEAVOR stent in subjects with a maximum of two de novo native @entity5 (lesion length  <= 40 mm, reference vessel diameter 2.25-4.00 mm). The primary end point was angiographic in-stent late loss at 8-month. The secondary end points were clinical outcomes at 2 years, including major adverse @entity4 ( @entity2 , @entity6 , or @entity1 revascularization) and stent @entity7 . RESULTS: Angiographic late lumen loss at 8 months in the TIVOLI group was superior to the ENDEAVOR group (in-stent (0.25    0.33) mm vs. (0.57    0.55) mm, diff (95%CI) -0.23 (-0.32, -0.14), P < 0.0001; in-segment (0.25    0.33) mm vs. (0.42    0.55) mm, diff (95%CI) -0.13 (-0.23, -0.02), P = 0.0083). The rate of in-stent binary restenosis at 8 months was reduced from 8.6% in the ENDEAVOR group to 2.9% in the TIVOLI group (P = 0.0229). Compared to ENDEAVOR stent, TIVOLI stent resulted in a significant reduction in @entity1 revascularization (4.2% vs. 9.6%, P = 0.0495) at 2 years. The two-year major adverse @entity4 (MACE) rate was lower for the TIVOLI group, but not significantly different (6.6% vs. 10.9%, P = 0.1630). CONCLUSIONS: TIVOLI was superior to ENDEAVOR stent with respect to late lumen loss at 8 months, and it yielded both lower rates of @entity3 at 8 months and @entity1 revascularization (TLR) at 2 years. The MACE rate at 2 years was comparable in both groups.

title: A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based XXXX -eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of @entity5 : 8-month angiographic and 2-year clinical follow-up results.

answer: @entity8


abstract: BACKGROUND: Available drug-eluting stents (DES) have achieved great success in reducing restenosis rates. Recently, investigators have demonstrated that the durable polymer carrier plays a significant role in DES-related hypersensitive reaction and delays vessel healing. TIVOLI stent is a novel @entity8 -eluting coronary stent with biodegradable coating containing @entity8 and @entity9 ( @entity9 ) polymer. The present study sought to evaluate the effectiveness and safety of the TIVOLI biodegradable-polymer-based @entity8 -eluting stent in treating @entity0 with @entity5 . METHODS: A prospective, multicenter clinical trial comparing TIVOLI biodegradable coated @entity8 -eluting stent with ENDEAVOR zotarolimus-eluting stent was conducted in 324 @entity0 (TIVOLI group: 168 @entity0 ; ENDEAVOR group: 156 @entity0 ) at 12 centers in China to demonstrate the non-inferiority of in-stent late loss with TIVOLI stent compared to ENDEAVOR stent in subjects with a maximum of two de novo native @entity5 (lesion length  <= 40 mm, reference vessel diameter 2.25-4.00 mm). The primary end point was angiographic in-stent late loss at 8-month. The secondary end points were clinical outcomes at 2 years, including major adverse @entity4 ( @entity2 , @entity6 , or @entity1 revascularization) and stent @entity7 . RESULTS: Angiographic late lumen loss at 8 months in the TIVOLI group was superior to the ENDEAVOR group (in-stent (0.25    0.33) mm vs. (0.57    0.55) mm, diff (95%CI) -0.23 (-0.32, -0.14), P < 0.0001; in-segment (0.25    0.33) mm vs. (0.42    0.55) mm, diff (95%CI) -0.13 (-0.23, -0.02), P = 0.0083). The rate of in-stent binary restenosis at 8 months was reduced from 8.6% in the ENDEAVOR group to 2.9% in the TIVOLI group (P = 0.0229). Compared to ENDEAVOR stent, TIVOLI stent resulted in a significant reduction in @entity1 revascularization (4.2% vs. 9.6%, P = 0.0495) at 2 years. The two-year major adverse @entity4 (MACE) rate was lower for the TIVOLI group, but not significantly different (6.6% vs. 10.9%, P = 0.1630). CONCLUSIONS: TIVOLI was superior to ENDEAVOR stent with respect to late lumen loss at 8 months, and it yielded both lower rates of @entity3 at 8 months and @entity1 revascularization (TLR) at 2 years. The MACE rate at 2 years was comparable in both groups.

title: A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based @entity8 -eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of XXXX : 8-month angiographic and 2-year clinical follow-up results.

answer: @entity5


abstract: INTRODUCTION: @entity10 is a major cause of lobar @entity7 in older adults, and of microvascular @entity2 . The rarest form of this disease is an inflammatory form causing @entity6 . It is important to recognize because the @entity0 usually respond to a brief course of immunosuppression. METHODS: Case report. RESULTS: A 66-year-old @entity0 developed gradual @entity3 , insidiously increasing headaches, and then had a likely @entity6 . MRI showed @entity1 , and innumerable superficial microhemorrhages characteristic of @entity9 . He was empirically treated with oral @entity4 and an anticonvulsant. His symptoms improved and the white matter @entity1 resolved over several months. @entity8 genotype was 4/4, which is commonly found in inflammatory @entity9 . CONCLUSIONS: Inflammatory @entity10 can be clinically diagnosed and treated without brain biopsy. Clinical diagnosis is important because of the good response to a brief course of @entity5 in most cases.

title: Clinical diagnosis and successful treatment of inflammatory XXXX .

answer: @entity10


abstract: BACKGROUND: A study was undertaken to evaluate results of surgery and radiotherapy (RT) for high-risk extracranial @entity2 . METHODS: Between 1986 and 2006, 60 @entity0 underwent surgery and RT for @entity3 . Preoperative RT (median, 50 gray [Gy]) and postoperative RT (median, 60 Gy) were used in 40% and 60% @entity0 , respectively. Sites included pelvis/lower extremity (48%), chest wall (22%), spine/paraspinal (17%), and head and neck (13%). Overall, median @entity1 size was 7 cm (range, 1-22 cm), and @entity1 grade was I, II, and III in 22%, 64%, and 14% of cases, respectively. RESULTS: Pathologically clear surgical margins (R0) were present in 50%, microscopic positive margins (R1) in 28%, and gross positive margins (R2) in 13%, half of whom had clinically detectable residual disease; surgical margin was unknown in 8%. Median follow-up was 75 months (range, 5-230 months). The crude local control rate was 90%. @entity0 with R0, R1, and R2 resections had local control of 100%, 94%, and 42%, respectively. Of the 8 cases that had R2 resection, 3 experienced uncontrolled progression, but 5 @entity0 had stable disease with long-term follow-up. The 10-year overall survival, progression-free survival, and cause-specific survival were 86%, 80.5%, and 89.4%, respectively. Younger age and @entity1 were associated with worse progression-free survival (P = .03 and .0003, respectively). CONCLUSIONS: Although surgery with complete resection is paramount in management of @entity2 , RT is a useful adjuvant treatment and appears to offer excellent and durable local control where wide surgical resection is difficult to accomplish.

title: High-risk extracranial XXXX : long-term results of surgery and radiation therapy.

answer: @entity2


abstract: PURPOSE: The aim of this study was to determine the incidence of winged scapula after @entity0 surgery, its impact on shoulder morbidity and difference in incidence according to surgery type. METHODS: @entity1 with @entity0 and surgical indication for axillary dissection were included. A total of 112 @entity1 were surveyed with one physical evaluation before the surgery and others 15, 30, 90, and 180  days after. Winged scapula was assessed with test proposed by Hoppenfeld. Shoulder range of motion (ROM) was assessed with goniometer for flexion, extension, adduction, abduction, internal rotation, and external rotation. A verbal scale from 0 to 10 was used to assess @entity2 . RESULTS: Winged scapula incidence was 8.0  % 15  days after surgery. Two @entity1 recovered from winged scapula 90  days after surgery and four more 180  days after surgery, while three @entity1 still had winged scapula at this time. The incidence after 15  days from surgery was 20.9 and 22.6  % among @entity1 submitted to sentinel node biopsy or axillary lymphadenectomy (AL), respectively (p   <   0.01). There was no statistical difference of incidence according to breast surgery type. Operated side shoulder flexion, adduction, and abduction ROM changes were statistically different in @entity1 with or without winged scapula. The mean reduction was higher in @entity1 with winged scapula. Both groups showed the same pattern over time in @entity2 . CONCLUSION: Winged scapula incidence was 8.0  % and was higher in AL, and prevalence decreased during 6  months after surgery. @entity1 who developed winged scapula had more shoulder flexion, adduction, and abduction limitation.

title: Winged scapula incidence and upper limb morbidity after surgery for XXXX with axillary dissection.

answer: @entity0


abstract: UNASSIGNED: We assessed the effect of single and repeated doses of bevacizumab, ranibizumab, and aflibercept on cell viability, proliferation, permeability, and apoptosis of @entity0 cells. @entity2 and @entity6 assays were used to determine viability and proliferation after single or repeated doses of anti- @entity1 drugs under normal and oxidative stress conditions. @entity4 expression after single and repeated doses of the 3 drugs was assessed using immunofluorescence. Transepithelial-electrical-resistance (TER) was measured to study the effect of anti-VEGFs on @entity5 ( @entity5 ) permeability under normal and oxidative stress conditions. Flow cytometry was used to detect intracellular accumulation of the drugs. Finally, a wound healing assay was performed to investigate the effect of the drugs on @entity5 cell migration. Single and multiple doses of anti- @entity1 drugs had no effect on cell viability and proliferation. The oxidative effect of @entity7 decreased cell viability and proliferation; however, no difference was observed between anti- @entity1 treatments. Immunofluorescence performed after single and repeated doses of the drugs revealed some @entity4 expression. Interestingly, anti-VEGFs restored the increased permeability induced by @entity7 . The 3 drugs accumulated inside the cells and were detectable 5days after treatment. Finally, none of the drugs affected migration. In conclusion, no measureable @entity3 effect was observed after single or repeated doses of @entity1 antagonists under normal and oxidative stress. Intracellular accumulation of the drugs does not seem to be @entity3 or affect cell functions. Our study suggests that anti-VEGFs could have a preventive effect on the maintenance of the @entity5 barrier under oxidative stress.

title: Single- and repeated-dose XXXX study of bevacizumab, ranibizumab, and aflibercept in @entity0 cells under normal and oxidative stress conditions.

answer: @entity3


abstract: UNASSIGNED: We assessed the effect of single and repeated doses of bevacizumab, ranibizumab, and aflibercept on cell viability, proliferation, permeability, and apoptosis of @entity0 cells. @entity2 and @entity6 assays were used to determine viability and proliferation after single or repeated doses of anti- @entity1 drugs under normal and oxidative stress conditions. @entity4 expression after single and repeated doses of the 3 drugs was assessed using immunofluorescence. Transepithelial-electrical-resistance (TER) was measured to study the effect of anti-VEGFs on @entity5 ( @entity5 ) permeability under normal and oxidative stress conditions. Flow cytometry was used to detect intracellular accumulation of the drugs. Finally, a wound healing assay was performed to investigate the effect of the drugs on @entity5 cell migration. Single and multiple doses of anti- @entity1 drugs had no effect on cell viability and proliferation. The oxidative effect of @entity7 decreased cell viability and proliferation; however, no difference was observed between anti- @entity1 treatments. Immunofluorescence performed after single and repeated doses of the drugs revealed some @entity4 expression. Interestingly, anti-VEGFs restored the increased permeability induced by @entity7 . The 3 drugs accumulated inside the cells and were detectable 5days after treatment. Finally, none of the drugs affected migration. In conclusion, no measureable @entity3 effect was observed after single or repeated doses of @entity1 antagonists under normal and oxidative stress. Intracellular accumulation of the drugs does not seem to be @entity3 or affect cell functions. Our study suggests that anti-VEGFs could have a preventive effect on the maintenance of the @entity5 barrier under oxidative stress.

title: Single- and repeated-dose @entity3 study of bevacizumab, ranibizumab, and aflibercept in XXXX cells under normal and oxidative stress conditions.

answer: @entity0


abstract: Accumulating evidence indicates a decisive role for the adjacent stroma in @entity1 growth and dissemination. However, it is not clear how far altered differentiation such as expression of aberrant keratins and @entity5 , common in invasive @entity0 @entity3 , may reflect intrinsic cell properties or a response to the @entity1 environment. We have addressed this by transplanting benign and malignant @entity0 HaCaT-ras keratinocytes, seeded on collagen matrix, onto @entity2 . Initially, epithelia derived from benign and malignant cells, being separated from host stroma by collagen, were poorly organized and exhibited the same differentiation markers, as identified by immunofluorescence and in situ hybridization. Epidermal basal and suprabasal keratins were expressed persistently even upon contact with newly formed stroma and malignant cell invasion. In contrast, non-epidermal keratins (K4/ @entity7 , K8/18, @entity6 ), which were similarly synthesized by benign and malignant cells in culture and in early transplants, were differentially regulated with increasing stromal vicinity. While both proteins and mRNAs were downregulated in benign epithelia, the malignant, invasive @entity1 cells continuously expressed these non-epidermal keratins throughout ( @entity6 ), suprabasally ( @entity4 ) or at invasive sites (K8/18). Furthermore, the mesenchymal protein @entity5 was expressed de novo in invasive areas confronting @entity1 stroma. Thus, atypical tissue markers, similarly synthesized in isolated cells in vitro, are downregulated in benign but maintained and upregulated in malignant epithelia. This is presumably caused by the neighbouring stroma being permanently activated by malignant epithelia.

title: Discriminating expression of differentiation markers evolves in transplants of benign and malignant XXXX skin keratinocytes through stromal interactions.

answer: @entity0


abstract: OBJECTIVES: This study aims to investigate the possible relationship between smoking and @entity12 in smokers, non-smokers and ex-smokers. @entity0 AND METHODS: Between March 01st, 2014 and March 31st, 2014, a total of 1,840 @entity0 (823 males, 1,017 females) over 25 years of age who were admitted to the ear nose, and throat (ENT) outpatient clinic were included in the study. The @entity0 who were smoking at least 10 cigarettes daily for at least five years were included in the smokers group (n=514). The @entity0 who did not smoke for at least one year following at least five years of smoking were included in the ex-smokers group (n=268). The @entity0 who never smoked were included in the non-smokers group (n=1,058). A form containing all ENT symptoms was given to all @entity0 and the @entity0 were asked to fill the form with their complaints following being informed by the same doctor. RESULTS: Cough, @entity8 , reflux, dryness of throat, irritation, @entity9 , bad breath, toothache, nasal congestion, @entity11 , snoring, and nasal discharge were found to be significantly higher in the smokers group, compared to the non-smokers group. Cough, sputum, hoarseness, @entity6 , reflux, sore throat, dryness of throat, irritation, stinging, oral aphthae, @entity9 , toothache, @entity5 gums, and bad breath were significantly lower in the ex-smokers group. Nasal congestion, nosebleeds, sneezing, nasal discharge, @entity11 , @entity1 , feeling of facial @entity13 , @entity10 , @entity4 , @entity2 , @entity13 , @entity7 , and @entity3 were statistically significantly lower in the ex-smokers group. CONCLUSION: Our study results show that smoking causes symptoms particularly associated with upper respiratory tract and these symptoms may persist in ex-smokers.

title: Relationship between smoking and XXXX .

answer: @entity12


abstract: BACKGROUND/AIMS: The aim of this study was to report results of @entity6 ( @entity6 ) in 5 consecutive @entity0 with cystic @entity1 and monitor long-term follow-up results. METHODOLOGY: Five cystic @entity1 @entity0 with multinodular @entity4 and complications of portal @entity2 (repeated variceal @entity3 refractory to endoscopic treatment) underwent @entity6 creation. There were 3 males and 2 females aged 8 to 18 years (median 14 yrs), their weight range was 27-51 (median 40) kg. A routine @entity6 technique was used. The @entity0 were followed by ultrasonography. RESULTS: The @entity6 was successfully performed in all five @entity0 . The mean portosystemic pressure gradient was reduced from 17 to 10 mmHg. There were no deaths related to the procedure. No clinical or laboratory signs of @entity3 into the gastrointestinal tract were observed in any @entity0 within the first 30 days following @entity6 . There was recurrent @entity3 6 times and asymptomatic stenoses were revealed by ultrasonography 15 times during a follow-up period of 15-81 (median 70) months. All stenoses were successfully dilated. One @entity0 had liver transplantation 15 months after @entity6 . Two @entity0 died 6.7 years and 4.5 years following the placement of @entity6 due to @entity5 . CONCLUSIONS: Symptomatic portal @entity2 was successfully managed with @entity6 in long-term follow-up; multiple reinterventions were required for shunt stenoses. @entity6 served as a bridge to liver transplantation in one case.

title: Transjugular intrahepatic portosystemic shunt in five @entity0 with cystic XXXX : long-term results.

answer: @entity1


abstract: BACKGROUND/AIMS: The aim of this study was to report results of @entity6 ( @entity6 ) in 5 consecutive @entity0 with cystic @entity1 and monitor long-term follow-up results. METHODOLOGY: Five cystic @entity1 @entity0 with multinodular @entity4 and complications of portal @entity2 (repeated variceal @entity3 refractory to endoscopic treatment) underwent @entity6 creation. There were 3 males and 2 females aged 8 to 18 years (median 14 yrs), their weight range was 27-51 (median 40) kg. A routine @entity6 technique was used. The @entity0 were followed by ultrasonography. RESULTS: The @entity6 was successfully performed in all five @entity0 . The mean portosystemic pressure gradient was reduced from 17 to 10 mmHg. There were no deaths related to the procedure. No clinical or laboratory signs of @entity3 into the gastrointestinal tract were observed in any @entity0 within the first 30 days following @entity6 . There was recurrent @entity3 6 times and asymptomatic stenoses were revealed by ultrasonography 15 times during a follow-up period of 15-81 (median 70) months. All stenoses were successfully dilated. One @entity0 had liver transplantation 15 months after @entity6 . Two @entity0 died 6.7 years and 4.5 years following the placement of @entity6 due to @entity5 . CONCLUSIONS: Symptomatic portal @entity2 was successfully managed with @entity6 in long-term follow-up; multiple reinterventions were required for shunt stenoses. @entity6 served as a bridge to liver transplantation in one case.

title: Transjugular intrahepatic portosystemic shunt in five XXXX with cystic @entity1 : long-term results.

answer: @entity0


abstract: BACKGROUND AND OBJECTIVE: We recently developed a new population pharmacokinetic model for @entity3 in @entity0 including age and bodyweight as covariates. The aim of the present study was to evaluate prospectively the predictive performance of this new model during @entity1 therapy. METHODS: This was a prospective, single-blinded, randomized, single-center study with two parallel arms. Fifty @entity0 aged 40-85  years undergoing cardiac surgery involving thoracotomy were enrolled. @entity3 was administered postoperatively on the intensive care unit as target controlled infusion (TCI) for @entity0 controlled analgesia (TCI-PCA) using the new pharmacokinetic model, or as conventional @entity0 controlled analgesia (PCA). Arterial blood samples were taken for measurement of the @entity3 plasma concentration. The predictive performance of the pharmacokinetic model was assessed by the @entity2 ( @entity2 ), the median absolute performance error (MDAPE), wobble and divergence. For comparison, the performance indices were also determined for three older models from the literature. RESULTS: 903 plasma concentrations of 41 @entity0 were analyzed. The mean values (95  % CI) of @entity2 , MDAPE, wobble and divergence for the new pharmacokinetic model were 11.2  % (3.9 to 18.7  %), 28.5  % (23.9 to 33.0  %), 21.4  % (18.0 to 24.9  %) and -1.6  %/h (-2.3 to -0.8  %/h). When compared with older models from the literature, performance was better with less overshoot after bolus doses. CONCLUSION: The new pharmacokinetic model of @entity3 showed a good precision and a better performance than older models. It is therefore suitable for TCI with @entity3 during @entity1 therapy. TRIAL REGISTRATION: EudraCT 2013-002875-16, Clinical Trials NCT02035709.

title: External Validation of a Recently Developed Population Pharmacokinetic Model for XXXX During Postoperative Pain Therapy.

answer: @entity3


abstract: UNASSIGNED: A cellulase-producing bacterium isolated from pulp and paper feedstock, Bacillus sp. AR03, was evaluated by means of a factorial design showing that peptone and @entity4 were the main variables affecting enzyme production. Simple @entity4 , individually and combined with @entity6 cellulose (CMC), were further examined for their influence on cellulase production by strain AR03. Most of the mono and @entity7 assayed presented a synergistic effect with CMC. As a result, a peptone-based broth supplemented with 10  g/L @entity0 and 10  g/L CMC maximized enzyme production after 96  h of cultivation. This medium was used to produce endoglucanases in a 1-L stirred tank reactor in batch mode at 30    C, which reduced the fermentation period to 48  h and reaching 3.12        0.02  IU/mL of enzyme activity. Bacillus sp. AR03 endoglucanases showed an optimum temperature of 60    C and a pH of 6.0 with a wide range of pH stability. Furthermore, presence of 10  mM @entity3 and 5  mM @entity2 produced an increase of enzyme activity (246.7 and 183.7  %, respectively), and remarkable tolerance to @entity5 , @entity8 , and @entity1 was also observed. According to our results, the properties of the cellulolytic cocktail from Bacillus sp. AR03 offer promising features in view of potential biorefinery applications.

title: Synergistic Effect of Simple Sugars and XXXX Cellulose on the Production of a Cellulolytic Cocktail from Bacillus sp. AR03 and Enzyme Activity Characterization.

answer: @entity6


abstract: The objective of this article is to describe the range of orthopaedic injuries and outcomes of acute treatment regimens among survivors of the USS COLE terrorist attack and to reemphasize basic treatment principles for @entity3 . With the current geopolitical environment, the average community orthopaedic surgeon may be involved in treating injuries due to an explosive terrorist attack. This is a retrospective review of a consecutive series of the 39 @entity0 who were injured during the USS COLE attack on October 12, 2000, and were received at Naval Medical Center, Portsmouth, Virginia, from the MEDEVAC (Medical Evacuation) system. The 17 casualties from the attack were not included in this study. Data were retrospectively collected from @entity0 charts for all @entity0 who survived the USS COLE attack. The 39 @entity0 who survived the USS COLE attack sustained 81 injuries. Fourteen @entity0 sustained 32 orthopaedic injuries, of which 61% were lower extremity injuries. Of the 10 @entity0 who required hospitalization, 6 had orthopaedic injuries (60%). Three of five @entity4 (60%) became infected, and two of two (100%) open @entity2 wounds treated with primary closure in the initial setting were infected. Lower @entity1 may predominate in a shipboard blast scenario. Even minor injuries require prolonged time before @entity0 return to active duty. Complex wounds have high infection rates and should be treated according to previously established protocols for wartime injuries. Principles of provisional @entity2 stabilization prior to transport, adequate wound d  bridement, and delayed wound closure are reviewed.

title: XXXX among survivors of USS COLE attack.

answer: @entity1


abstract: Virginia Stephen was a member of one of England's great literary families, many of whom were also mentally ill. An exquisitely endowed @entity0 , she was beautifully matched with her mother during the symbiotic state of development, and later called this period "the base upon which life stands." Difficulties presumably began as early as the differentiation subphase of separation. Mrs. Stephen appeared to be a narcissistic @entity0 , who required constant affirmation, and thus was unable to respond to the needs of a developing @entity0 . Virginia probably was rescued from engulfment by a powerful biologically determined practicing period of separation-individuation. This great organismic surge, in all likelihood, is as characteristic of toddlers who are incipient manics as of @entity0 of future genius. Because of the strong regressive pull, it is probable that Virginia experienced a particularly high-powered glee in evading the field of her mother. This "economic condition," according to Freud, is a given that is felt by the @entity1 as he overthrows the imprisoning restraints of the superego. Deflated by events beyond her control, such as the sadism of her siblings, Virginia probably attempted to return to her mother. But it appears that Mrs. Stephen was not available. Hence Virginia was forced to split off her anger and turn it against herself, keeping her aggression unavailable for neutralization. As a result she was unable to proceed to an age-adequate level of development. The raw rage lay smoldering within until many years later, when it burst forth to power her @entity1 attacks. This failure of rapprochement presumably deflated Virginia, and resulted in a basic mood of @entity2 already apparent in the nursery. Virginia also experienced a second basic mood, elation, which appears to have been characteristic of her even in well periods, and resembles the description of the typical @entity1 victim given by Beck.

title: Virginia Woolf: XXXX and genius. An illustration of separation-individuation theory.

answer: @entity1


abstract: BACKGROUND: Previous work has suggested an increase in risk of @entity6 ( @entity6 ) and @entity4 among workers exposed to extremely low-frequency magnetic fields (ELF-MF). We evaluated the relation between ELF-MF from occupational exposures and mortality from @entity2 . METHODS: The study was based on a cohort of Swedish engineering industry workers, comprising 537,692 @entity0 and 180,529 @entity0 . The cohort was matched against the 3 most recent censuses and The Causes of Death Registry. Levels of ELF-MF exposure were obtained by linking occupation according to the censuses to a job exposure matrix. We used 4 levels of exposure and considered both the primary and contributing causes of @entity5 , 1985-96. RESULTS: The risk of @entity4 as primary or contributing cause of @entity5 increased with increasing exposure to ELF-MF among both @entity0 and @entity0 , with a relative risk (RR) of 4.0 and a 95% confidence interval (95% CI) of 1.4-11.7 in the highest exposure group for both sexes combined. There was a RR of 2.2 (95% CI: 1.0-4.7) for @entity6 in the highest exposure group with the suggestion of an exposure-response relationship. No evidence of increased risk was seen for @entity3 or @entity1 . CONCLUSIONS: The findings support previous observations of an increased risk of @entity4 and @entity6 among employees occupationally exposed to ELF-MF. Further studies based on morbidity data are warranted.

title: XXXX in welders and other workers exposed to high levels of magnetic fields.

answer: @entity2


abstract: Intermittent fasting (IF) reportedly increases resistance and intestinal IgA response to @entity2 infection in mature @entity0 . The aim of this study was to explore the effect of aging on the aforementioned improved immune response found with IF. Middle-aged male BALB/c @entity0 were submitted to IF or ad libitum (AL) feeding for 40  weeks and then orally infected with @entity2 . Thereafter, infected animals were all fed AL (to maximize their viability) until sacrifice on day 7 or 14 @entity1 . We evaluated body weight, bacterial load (in feces, Peyer's patches, spleen and liver), total and specific intestinal IgA, lamina propria IgA+ plasma cells, plasma @entity3 , and messenger RNA (mRNA) expression of a-chain, J-chain, and the polymeric immunoglobulin receptor (pIgR) in liver and intestinal mucosa. In comparison with the infected AL counterpart, the infected IF group (long-term IF followed by @entity1 AL feeding) generally had lower intestinal and systemic bacterial loads as well as higher total IgA on both @entity1 days. Both infected groups showed no differences in @entity3 levels, body weight, or food and caloric intake. The increase in intestinal IgA was associated with enhanced pIgR mRNA expression in the intestine (day 7) and liver. Thus, to maintain body weight and caloric intake, IF elicited metabolic signals that possibly induced the increased hepatic and intestinal pIgR mRNA expression found. The increase in IgA probably resulted from intestinal IgA transcytosis via pIgR. This IgA response along with phagocyte-induced killing of bacteria in systemic organs (not measured) may explain the resolution of the @entity2 infection.

title: Intermittent fasting favored the resolution of XXXX infection in middle-aged BALB/c @entity0 .

answer: @entity2


abstract: Intermittent fasting (IF) reportedly increases resistance and intestinal IgA response to @entity2 infection in mature @entity0 . The aim of this study was to explore the effect of aging on the aforementioned improved immune response found with IF. Middle-aged male BALB/c @entity0 were submitted to IF or ad libitum (AL) feeding for 40  weeks and then orally infected with @entity2 . Thereafter, infected animals were all fed AL (to maximize their viability) until sacrifice on day 7 or 14 @entity1 . We evaluated body weight, bacterial load (in feces, Peyer's patches, spleen and liver), total and specific intestinal IgA, lamina propria IgA+ plasma cells, plasma @entity3 , and messenger RNA (mRNA) expression of a-chain, J-chain, and the polymeric immunoglobulin receptor (pIgR) in liver and intestinal mucosa. In comparison with the infected AL counterpart, the infected IF group (long-term IF followed by @entity1 AL feeding) generally had lower intestinal and systemic bacterial loads as well as higher total IgA on both @entity1 days. Both infected groups showed no differences in @entity3 levels, body weight, or food and caloric intake. The increase in intestinal IgA was associated with enhanced pIgR mRNA expression in the intestine (day 7) and liver. Thus, to maintain body weight and caloric intake, IF elicited metabolic signals that possibly induced the increased hepatic and intestinal pIgR mRNA expression found. The increase in IgA probably resulted from intestinal IgA transcytosis via pIgR. This IgA response along with phagocyte-induced killing of bacteria in systemic organs (not measured) may explain the resolution of the @entity2 infection.

title: Intermittent fasting favored the resolution of @entity2 infection in middle-aged BALB/c XXXX .

answer: @entity0


abstract: A combination of immuno-electron microscopy and electron energy-loss spectrum-imaging was used to map the distributions of endocrine polypeptide hormones and proteins in @entity0 pancreatic islet of Langerhans. Tissue was analyzed from control animals and from @entity0 that were heterozygous for the @entity7 gene, which defines a @entity1 / @entity4 -dependent membrane fusion and ion channel protein. The heterozygous @entity7 (+/-) @entity0 displays defects in @entity6 mediated @entity1 signaling and insulin secretion. Therefore, information was obtained about the distributions of the hormones insulin and glucagon, as well as the proteins @entity7 and the @entity6 . Insulin secretion appears to be defective in the mutants. It was found from immunolabeling experiments that expression of the @entity6 is reduced in mutant islets compared to control islets. Subcellular distributions of @entity2 and @entity3 obtained by electron energy-loss spectrum-imaging showed that the insulin concentrations of beta granules were essentially the same in control and mutant islets. By contrast, immunogold labeling of mutant islets shows more insulin immunoreactivity in the beta granules. It follows that insulin may be packaged differently in mutant islets, making antigenic determinants more available to the labeling antibody. The increased rate of insulin secretion in the @entity5 mutant islets can be explained by compensatory increases in islet size, rather than by an increased insulin concentration in the beta cells. The results indicate that reduced @entity7 expression leads to defects in the @entity6 expression in the endocrine cells of the mutant @entity0 . Increased size of the islet or of adrenal medulla may be a compensatory mechanism for secretion defect by individual endocrine cells. Defects in @entity6 expression, and documented consequences of a @entity1 signaling defect, lead to other changes in organelles such as the mitochondrial number in islet beta-cells. The effects and consequences of reduced @entity7 expression on mitochondria are evident in ultrastructural observations.

title: Mapping protein expression in XXXX pancreatic islets by immunolabeling and electron energy loss spectrum-imaging.

answer: @entity0


abstract: Comparative genomic hybridization (CGH) of @entity2 frequently shows gains and amplifications of chromosome 20. However, the underlying @entity1 is unknown and conventional CGH results do not allow specification of the target region. In order to investigate this chromosomal aberration with a higher resolution and sensitivity, microarray-based CGH was performed with both scanning and high-resolution arrays of chromosome 20 in a series of 27 @entity2 . Locus-specific fragments of genomic DNA from bacterial artificial chromosome (BAC) clones were spotted as microarrays. A scanning array contained a set of 27 BAC clones covering chromosome 20q. A high-resolution array contained 27 overlapping BAC clones at 20q13.2. This high-resolution array was used to narrow down the amplicon at 20q13.2 in @entity0 showing amplification of this chromosomal region with the scanning array. Positive copy number changes on chromosome 20q were detected in 12 of 27 cases (44%). These changes included gain of the whole arm of chromosome 20q in 8 of 27 (30%) cases, amplification restricted to 20q12.1 in one case, and amplifications restricted to 20q13 in three cases (11%). The three @entity0 showing amplification restricted to 20q13 were analysed further using the high-resolution array. In one @entity0 , the whole contig was amplified at a constant level. One of the other two @entity0 had a clear proximal breakpoint, while the other @entity0 had a clear distal breakpoint within the 20q13.2 region. The proximal and the distal breakpoint were approximately 800 kb apart. In the present study, an amplicon at 20q13.2 has been narrowed down to 800 kb which is likely to harbour one or more putative oncogenes relevant to @entity2 , for which @entity4 and @entity3 are good candidates.

title: Determination of amplicon boundaries at 20q13.2 in tissue samples of human XXXX by high-resolution microarray comparative genomic hybridization.

answer: @entity2


abstract: @entity4 is associated with a high @entity2 -related mortality due to the propensity to develop @entity1 . The mechanisms that are responsible for malignant dissemination are largely unknown and need to be explored to facilitate diagnosis and treatment of @entity1 . To identify molecules involved in dissemination, we used cell lines derived from a primary @entity4 and 2 liver @entity1 from the same @entity0 as a model for @entity2 progression. Using a microarray representing 1,176 genes, we identified 63 differentially expressed genes. Forty genes showed a higher expression and 23 showed a lower expression in the primary cell line compared to the @entity1 cell lines. These genes are involved in processes like angiogenesis, apoptosis, macrophage stimulation, and extracellular matrix regulation. In contrast, the 2 liver @entity1 cell lines produced nearly identical expression profiles. Demethylation of the primary @entity3 cell line by @entity6 treatment revealed that 19 genes were suppressed by hypermethylation. An important finding was the 5-fold decreased expression of @entity5 in the metastatic cell lines, a molecule involved in extracellular matrix degradation. We demonstrate in the cell lines that @entity5 expression is regulated by methylation. These observations were confirmed in primary @entity4 and suggests a role for @entity5 in @entity4 development.

title: Expression profiling reveals that methylation of XXXX is involved in @entity4 development.

answer: @entity5


abstract: @entity4 is associated with a high @entity2 -related mortality due to the propensity to develop @entity1 . The mechanisms that are responsible for malignant dissemination are largely unknown and need to be explored to facilitate diagnosis and treatment of @entity1 . To identify molecules involved in dissemination, we used cell lines derived from a primary @entity4 and 2 liver @entity1 from the same @entity0 as a model for @entity2 progression. Using a microarray representing 1,176 genes, we identified 63 differentially expressed genes. Forty genes showed a higher expression and 23 showed a lower expression in the primary cell line compared to the @entity1 cell lines. These genes are involved in processes like angiogenesis, apoptosis, macrophage stimulation, and extracellular matrix regulation. In contrast, the 2 liver @entity1 cell lines produced nearly identical expression profiles. Demethylation of the primary @entity3 cell line by @entity6 treatment revealed that 19 genes were suppressed by hypermethylation. An important finding was the 5-fold decreased expression of @entity5 in the metastatic cell lines, a molecule involved in extracellular matrix degradation. We demonstrate in the cell lines that @entity5 expression is regulated by methylation. These observations were confirmed in primary @entity4 and suggests a role for @entity5 in @entity4 development.

title: Expression profiling reveals that methylation of @entity5 is involved in XXXX development.

answer: @entity4


abstract: Eleven unique monoclonal IgG antibodies were raised against @entity2 brain acetylcholinesterase ( @entity5 , EC 3.1.1.7), purified to electrophoretic homogeneity by a two-step procedure involving immunoaffinity chromatography. The apparent dissociation constants of these antibodies for @entity2 @entity5 ranged from about 10 nM to more than 100 nM (assuming one binding site per catalytic subunit). Species cross-reactivity was investigated with crude brain extracts from @entity2 , @entity1 , @entity0 cat, @entity3 , and human. One antibody bound @entity2 @entity5 exclusively; most bound @entity5 from three or four species; two bound enzyme from all species tested. Identical, moderate affinity for @entity1 and @entity0 brain @entity5 was displayed by two antibodies; two others were able to distinguish between these similar antigens. Nine of the antibodies had lowered affinity for @entity5 in the presence of 1 M @entity4 , but two were salt resistant. Analysis of mutual interferences in @entity5 binding suggested that certain of the antibodies were competing for nearby epitopes on the @entity5 surface. One antibody was a potent @entity5 inhibitor (IC50 = 10(-8) M), blocking up to 90% of the enzyme activity. Most of the antibodies were less able to bind the readily soluble @entity5 of detergent-free brain extracts than the @entity5 which required detergent for solubilization. The extreme case, an antibody that was unable to recognize nearly half of the "soluble" @entity5 , was suspected of lacking affinity for the hydrophilic enzyme form.

title: Monoclonal antibodies to XXXX brain acetylcholinesterase: selective enzyme inhibition, differential affinity for enzyme forms, and cross-reactivity with other mammalian cholinesterases.

answer: @entity2


abstract: Aim. To investigate the correlation and significance between the urine soluble Fas (sFas) and @entity2 ( @entity2 ) expression in @entity0 with @entity3 ( @entity3 ). Methods. The level of sFas was measured by enzyme-linked immunosorbent assay (ELISA) and the expression of @entity2 protein in @entity3 surgical specimens was screened by immunohistochemical method. These data were analyzed through SPSS 13.0 software. Results. The urinary sFas levels were significantly higher in the @entity0 with @entity3 than in those without @entity1 (168.0   ng/mL    84.6 versus 56.2   ng/mL    37.0; P < 0.05) and in the cases with a higher stage or grade than in those with a lower stage or grade (each P < 0.05). They had a positive relationship between the expression of @entity2 protein and the pathological stage or grade in @entity3 tissues (each P < 0.05). Spearman rank correlation test showed a significant correlation between sFas levels and @entity2 expressions (R = 0.882, P < 0.05). Conclusions. The effects of sFas and @entity2 may play important roles together in the occurrence and progression of @entity3 . Joint detection of urine sFas plus @entity2 protein may provide valuable solutions to improve the diagnosis and treatment of @entity3 .

title: Correlation and Significance of Urinary Soluble Fas and XXXX in Bladder @entity1 .

answer: @entity2


abstract: Aim. To investigate the correlation and significance between the urine soluble Fas (sFas) and @entity2 ( @entity2 ) expression in @entity0 with @entity3 ( @entity3 ). Methods. The level of sFas was measured by enzyme-linked immunosorbent assay (ELISA) and the expression of @entity2 protein in @entity3 surgical specimens was screened by immunohistochemical method. These data were analyzed through SPSS 13.0 software. Results. The urinary sFas levels were significantly higher in the @entity0 with @entity3 than in those without @entity1 (168.0   ng/mL    84.6 versus 56.2   ng/mL    37.0; P < 0.05) and in the cases with a higher stage or grade than in those with a lower stage or grade (each P < 0.05). They had a positive relationship between the expression of @entity2 protein and the pathological stage or grade in @entity3 tissues (each P < 0.05). Spearman rank correlation test showed a significant correlation between sFas levels and @entity2 expressions (R = 0.882, P < 0.05). Conclusions. The effects of sFas and @entity2 may play important roles together in the occurrence and progression of @entity3 . Joint detection of urine sFas plus @entity2 protein may provide valuable solutions to improve the diagnosis and treatment of @entity3 .

title: Correlation and Significance of Urinary Soluble Fas and @entity2 in Bladder XXXX .

answer: @entity1


abstract: Clinical efficacy and safety of the drug impase in @entity1 ( @entity1 ) were studied in 30 @entity0 with @entity1 of various genesis (mean age 52.09 +/- 4.75 years). IIED questionnairing was employed, combined andrological examination and standard laboratory investigations. Impase was taken 1 tablet a day each other day for 12 weeks irrespective of the intercourse. The number of attempted intercourses was at least 4 times a month. The treatment efficacy was assessed by changes of IIED parameters, subjective and objective effects. @entity1 was psychogenic in 5 (16.7%) @entity0 , organic in 25 (83.3%) @entity0 . Blood hormones were normal for age in all the @entity0 . According to IIED, "erectile function" mean score after 12 week treatment rose from 18.89 +/- 5.25 to 22.50 +/- 4.86. In 11 (36.7%), 4 (13.3%), 5 (16.7%) @entity0 the response was rated as excellent, good and satisfactory, respectively. No response was stated in 10 (33.3%) @entity0 . Side effects were absent. Tolerance and safety were excellent. Thus, efficacy of impase therapy varied from 60 to 66.7% depending on @entity1 etiology and pathogenesis. Cost-efficacy, absence of side effects, possible parallel therapy of concurrent diseases, course administration are advantages of the treatment.

title: [An open non-comparative study of impase for treating XXXX ].

answer: @entity1


abstract: CONTEXT: Lower plasma b-amyloid 42 and 42/40 levels have been associated with incident @entity3 , but results are conflicting and few have investigated @entity2 among elders without @entity3 . OBJECTIVE: To determine if plasma b-amyloid is associated with @entity2 and if this association is modified by measures of cognitive reserve. DESIGN, SETTING, AND @entity0 : We studied 997 black and white community-dwelling older adults from Memphis, Tennessee, and Pittsburgh, Pennsylvania, who were enrolled in the Health ABC Study, a prospective observational study begun in 1997-1998 with 10-year follow-up in 2006-2007. @entity0 mean age was 74.0 (SD, 3.0) years; 55.2% (n = 550) were female; and 54.0% (n = 538) were black. MAIN OUTCOME MEASURES: Association of near-baseline plasma b-amyloid levels (42 and 42/40 measured in 2010) and repeatedly measured Modified Mini-Mental State Examination (3MS) results. RESULTS: Low b-amyloid 42/40 level was associated with greater 9-year 3MS @entity2 (lowest b-amyloid tertile: mean change in 3MS score, -6.59 [95% confidence interval [CI], -5.21 to -7.67] points; middle tertile: -6.16 [95% CI, -4.92 to -7.32] points; and highest tertile: -3.60 [95% CI, -2.27 to -4.73] points; P < .001). Results were similar after multivariate adjustment for age, race, education, @entity1 , smoking, and @entity4 [ @entity4 ] e4 status and after excluding the 72 @entity0 with incident @entity3 . Measures of cognitive reserve modified this association whereby among those with high reserve (at least a high school diploma, higher than sixth-grade literacy, or no @entity4 e4 allele), b-amyloid 42/40 was less associated with multivariate adjusted 9-year decline. For example, among @entity0 with less than a high school diploma, the 3MS score decline was -8.94 (95% CI, -6.94 to -10.94) for the lowest tertile compared with -4.45 (95% CI, -2.31 to -6.59) for the highest tertile, but for those with at least a high school diploma, 3MS score decline was -4.60 (95% CI,-3.07 to -6.13) for the lowest tertile and -2.88 (95% CI,-1.41 to -4.35) for the highest tertile (P = .004 for interaction). Interactions were also observed for literacy (P = .005) and for @entity4 e4 allele (P = .02). CONCLUSION: Lower plasma b-amyloid 42/40 is associated with greater @entity2 among elderly @entity0 without @entity3 over 9 years, and this association is stronger among those with low measures of cognitive reserve.

title: Association of plasma beta-amyloid level and cognitive reserve with subsequent XXXX .

answer: @entity2


abstract: PURPOSE: To analyze the @entity4 and patterns of failure of proton therapy given in ablative doses for medically inoperable early-stage @entity7 ( @entity7 ). METHODS AND MATERIALS: Eighteen @entity0 with medically inoperable T1N0M0 (central location) or T2-3N0M0 (any location) @entity7 were treated with proton therapy at 87.5 Gy (relative biological effectiveness) at 2.5 Gy /fraction in this Phase I/II study. All @entity0 underwent treatment simulation with four-dimensional CT; internal gross @entity2 volumes were delineated on maximal intensity projection images and modified by visual verification of the target volume in 10 breathing phases. The internal gross @entity2 volumes with maximal intensity projection density was used to design compensators and apertures to account for @entity2 motion. Therapy consisted of passively scattered protons. All @entity0 underwent repeat four-dimensional CT simulations during treatment to assess the need for adaptive replanning. RESULTS: At a median follow-up time of 16.3 months (range, 4.8-36.3 months), no @entity0 had experienced Grade 4 or 5 @entity4 . The most common adverse effect was @entity9 (Grade 2, 67%; Grade 3, 17%), followed by Grade 2 @entity8 (44%), Grade 2 @entity3 (11%), Grade 2 @entity10 (6%), and Grade 2 chest wall @entity5 (6%). Rates of local control were 88.9%, regional lymph node failure 11.1%, and distant metastasis 27.8%. Twelve @entity0 (67%) were still alive at the last follow-up; five had died of @entity1 and one of preexisting @entity6 . CONCLUSIONS: Proton therapy to ablative doses is well tolerated and produces promising local control rates for medically inoperable early-stage @entity7 .

title: XXXX and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable @entity7 .

answer: @entity4


abstract: PURPOSE: To analyze the @entity4 and patterns of failure of proton therapy given in ablative doses for medically inoperable early-stage @entity7 ( @entity7 ). METHODS AND MATERIALS: Eighteen @entity0 with medically inoperable T1N0M0 (central location) or T2-3N0M0 (any location) @entity7 were treated with proton therapy at 87.5 Gy (relative biological effectiveness) at 2.5 Gy /fraction in this Phase I/II study. All @entity0 underwent treatment simulation with four-dimensional CT; internal gross @entity2 volumes were delineated on maximal intensity projection images and modified by visual verification of the target volume in 10 breathing phases. The internal gross @entity2 volumes with maximal intensity projection density was used to design compensators and apertures to account for @entity2 motion. Therapy consisted of passively scattered protons. All @entity0 underwent repeat four-dimensional CT simulations during treatment to assess the need for adaptive replanning. RESULTS: At a median follow-up time of 16.3 months (range, 4.8-36.3 months), no @entity0 had experienced Grade 4 or 5 @entity4 . The most common adverse effect was @entity9 (Grade 2, 67%; Grade 3, 17%), followed by Grade 2 @entity8 (44%), Grade 2 @entity3 (11%), Grade 2 @entity10 (6%), and Grade 2 chest wall @entity5 (6%). Rates of local control were 88.9%, regional lymph node failure 11.1%, and distant metastasis 27.8%. Twelve @entity0 (67%) were still alive at the last follow-up; five had died of @entity1 and one of preexisting @entity6 . CONCLUSIONS: Proton therapy to ablative doses is well tolerated and produces promising local control rates for medically inoperable early-stage @entity7 .

title: @entity4 and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable XXXX .

answer: @entity7


abstract: @entity2 antagonist therapy is associated with a risk of severe, extrapulmonary, disseminated @entity3 , which is fatal in 10% of cases. The risk of @entity3 is increased four-fold in @entity0 on @entity2 antagonist therapy. The main risk factors are a history of untreated or inadequately treated @entity3 , recent contact with a @entity3 @entity0 , and residence in or travel to a high-endemicity region. Infection surveillance agencies throughout the world have issued recommendations to ensure the detection and treatment of @entity5 before @entity2 antagonist initiation. These recommendations have returned the incidence of @entity3 to the level seen before the introduction of @entity2 antagonists. Nevertheless, there is still room for improvement. Recommendations about @entity5 screening include the use of tuberculin skin tests. However, these tests are positive in individuals vaccinated with the BCG vaccine, which leads to overuse of @entity3 chemoprophylaxis and, therefore, to unnecessary @entity0 exposure to hepatotoxic effects. Furthermore, tuberculin skin tests may be falsely negative in immunosuppressed @entity0 , leading to underuse of @entity3 prophylaxis. These shortcomings of tuberculin skin tests have generated interest in @entity4 release assays (IGRAs). In @entity0 with overt @entity3 , IGRAs are more sensitive and more specific than tuberculin skin tests. However, the accuracy of IGRAs for diagnosing @entity5 remains unknown, because no reference standard is available. In addition, @entity0 taking immunosuppressant agents to treat @entity1 may exhibit anergia, which complicates the interpretation of IGRAs. Until additional data become available, caution requires that IGRAs be used only when a positive or negative result, as assessed on a case-by-case basis, will help to decide whether @entity3 chemoprophylaxis is in order.

title: Role for @entity4 release assays in @entity5 screening before XXXX antagonist therapy.

answer: @entity2


abstract: @entity2 antagonist therapy is associated with a risk of severe, extrapulmonary, disseminated @entity3 , which is fatal in 10% of cases. The risk of @entity3 is increased four-fold in @entity0 on @entity2 antagonist therapy. The main risk factors are a history of untreated or inadequately treated @entity3 , recent contact with a @entity3 @entity0 , and residence in or travel to a high-endemicity region. Infection surveillance agencies throughout the world have issued recommendations to ensure the detection and treatment of @entity5 before @entity2 antagonist initiation. These recommendations have returned the incidence of @entity3 to the level seen before the introduction of @entity2 antagonists. Nevertheless, there is still room for improvement. Recommendations about @entity5 screening include the use of tuberculin skin tests. However, these tests are positive in individuals vaccinated with the BCG vaccine, which leads to overuse of @entity3 chemoprophylaxis and, therefore, to unnecessary @entity0 exposure to hepatotoxic effects. Furthermore, tuberculin skin tests may be falsely negative in immunosuppressed @entity0 , leading to underuse of @entity3 prophylaxis. These shortcomings of tuberculin skin tests have generated interest in @entity4 release assays (IGRAs). In @entity0 with overt @entity3 , IGRAs are more sensitive and more specific than tuberculin skin tests. However, the accuracy of IGRAs for diagnosing @entity5 remains unknown, because no reference standard is available. In addition, @entity0 taking immunosuppressant agents to treat @entity1 may exhibit anergia, which complicates the interpretation of IGRAs. Until additional data become available, caution requires that IGRAs be used only when a positive or negative result, as assessed on a case-by-case basis, will help to decide whether @entity3 chemoprophylaxis is in order.

title: Role for XXXX release assays in @entity5 screening before @entity2 antagonist therapy.

answer: @entity4


abstract: @entity2 antagonist therapy is associated with a risk of severe, extrapulmonary, disseminated @entity3 , which is fatal in 10% of cases. The risk of @entity3 is increased four-fold in @entity0 on @entity2 antagonist therapy. The main risk factors are a history of untreated or inadequately treated @entity3 , recent contact with a @entity3 @entity0 , and residence in or travel to a high-endemicity region. Infection surveillance agencies throughout the world have issued recommendations to ensure the detection and treatment of @entity5 before @entity2 antagonist initiation. These recommendations have returned the incidence of @entity3 to the level seen before the introduction of @entity2 antagonists. Nevertheless, there is still room for improvement. Recommendations about @entity5 screening include the use of tuberculin skin tests. However, these tests are positive in individuals vaccinated with the BCG vaccine, which leads to overuse of @entity3 chemoprophylaxis and, therefore, to unnecessary @entity0 exposure to hepatotoxic effects. Furthermore, tuberculin skin tests may be falsely negative in immunosuppressed @entity0 , leading to underuse of @entity3 prophylaxis. These shortcomings of tuberculin skin tests have generated interest in @entity4 release assays (IGRAs). In @entity0 with overt @entity3 , IGRAs are more sensitive and more specific than tuberculin skin tests. However, the accuracy of IGRAs for diagnosing @entity5 remains unknown, because no reference standard is available. In addition, @entity0 taking immunosuppressant agents to treat @entity1 may exhibit anergia, which complicates the interpretation of IGRAs. Until additional data become available, caution requires that IGRAs be used only when a positive or negative result, as assessed on a case-by-case basis, will help to decide whether @entity3 chemoprophylaxis is in order.

title: Role for @entity4 release assays in XXXX screening before @entity2 antagonist therapy.

answer: @entity5


abstract: OBJECTIVE: To reduce the recurrent rate of the nasal @entity2 (NIP), the staging system of the NIP and the select criterion of surgical approaches were researched. METHOD: Based on the feature of the @entity1 and CT examination, forty-one cases of NIP were divided into T1, T2, T3, T4. Nineteen @entity0 were treated endoscopically. Twenty @entity0 were undergone lateral rhinotomy. Two @entity0 were treated with medial maxillectomy. RESULT: Recurrent rate of the endoscopic management was 10.5%. Recurrent rate of the lateral rhinotomy was 15.0%. CONCLUSION: The disease of the T1, T2, T3a can be treated by endoscopic management. The disease of the T3b, T4 can be treated by lateral rhinotomy or other approach. The selection of the surgical approach depended on the @entity1 clinical staging system.

title: [Clinical staging system and surgical treatment for nasal XXXX ].

answer: @entity2


abstract: BACKGROUND: The utility of defibrillation threshold testing in @entity0 undergoing @entity5 ( @entity5 ) implantation is controversial. Higher defibrillation thresholds have been noted in @entity0 undergoing implantation of @entity2 ( @entity2 ). Since the risks and potential benefits of testing may be higher in this population, we sought to assess the impact of defibrillation safety margin or vulnerability safety margin testing in @entity2 recipients. METHODS AND RESULTS: A total of 256 consecutive subjects who underwent @entity2 implantation between January 2003 and December 2007 were retrospectively reviewed. Subjects were divided into two groups based on whether (n= 204) or not (n= 52) safety margin testing was performed. @entity0 characteristics, @entity3 therapies, procedural results, and clinical outcomes were recorded. Baseline characteristics, including @entity4 ( @entity4 ) severity, were comparable between the groups. Four cases of @entity4 exacerbation (2%), including one leading to one @entity1 , were recorded in the tested group immediately post-implantation. No complications were observed in the untested group. After a mean follow-up of 32    20 months, the proportion of appropriate shocks in the two groups was similar (31 vs. 25%, P = 0.49). There were three cases of failed appropriate shocks in the tested group, despite adequate safety margins at implantation, whereas no failed shocks were noted in the untested group. Survival was similar in the two groups. CONCLUSION: Defibrillation efficacy testing during implant of @entity2 was associated with increased morbidity and did not predict the success of future device therapy or improve survival during long-term follow-up.

title: Defibrillation threshold testing fails to show clinical benefit during long-term follow-up of XXXX undergoing cardiac resynchronization therapy defibrillator implantation.

answer: @entity0


abstract: High-risk @entity7 )-associated @entity2 of the uterine cervix is a particularly useful model to study basic mechanisms of genomic instability in @entity1 . Cervical @entity2 is associated with the expression of two high-risk HPV-encoded oncoproteins, E6 and E7. Aneuploidy, the most frequent form of genomic instability in @entity0 @entity3 , develops as early as in nonmalignant cervical precursor lesions. In addition, cervical @entity1 is frequently associated with abnormal multipolar mitotic figures, suggesting disturbances of the cell-division process as a mechanism for chromosome segregation defects. Spindle poles are formed by centrosomes, and the high-risk HPV E6 and E7 oncoproteins can each induce @entity4 . These two HPV oncoproteins, however, induce centrosome abnormalities through fundamentally different mechanisms and, presumably, with different functional consequences. High-risk HPV E7, which targets the @entity6 @entity1 suppressor pathway, can provoke abnormal centrosome duplication in phenotypically normal cells. On the contrary, cells expressing the HPV E6 oncoprotein, which inactivates @entity5 , accumulate abnormal numbers of centrosomes in parallel with multinucleation and nuclear atypia. These two pathways are not mutually exclusive, since co-expression of HPV E6 and E7 has synergistic effects on centrosome abnormalities and chromosomal instability. Taken together, these findings support the general model in which chromosomal instability arises as a direct consequence of oncogenic insults and can develop at early stages of @entity1 progression.

title: Centrosomes, genomic instability, and cervical XXXX .

answer: @entity2


abstract: Autoantibodies have defined two paraneoplastic @entity4 related to @entity3 : @entity8 ("CAR"-IgG [23kDa, @entity16 ]) and @entity14 collapsin response-mediated protein 5 ( @entity15 -IgG [62kDa]). Among 16 @entity0 with @entity15 -IgG and @entity14 (aged 52-74 years; all smokers, 9 @entity0 ), we documented coexisting @entity11 in 5. None had CAR-IgG. Fifteen had subacute @entity9 , swollen optic discs, and field defects. Vascular leakage was evident at and remote from the disc; 5/5 tested had abnormal electroretinograms. Nine had striking vitreous cells. Vitrectomy showed @entity13 (4/4), predominantly @entity5 (+) (1/1). Most @entity0 had multifocal neurological accompaniments. Cerebrospinal fluid contained lymphocytes (7-32), elevated protein, multiple oligoclonal immunoglobulin bands, and @entity15 -IgG. Three @entity0 superficially resembled @entity10 at presentation. One autopsied @entity0 had predominantly @entity6 (+) T lymphocytes infiltrating optic nerve and spinal cord. Eleven @entity0 had confirmed @entity12 ; 1 had imaging evidence of @entity1 ; 3 had @entity7 . Full-length @entity15 protein was identified in normal retina and optic nerve by Western blot analyses. Photoreceptor cells, retinal ganglion cells, and nerve fibers exhibited @entity15 -specific immunoreactivity. In summary, @entity15 -IgG defines a paraneoplastic ophthalmological entity of combined @entity14 and @entity11 with vitreous inflammatory cells. Positive serology obviates the need for vitreous biopsy and expedites the search for @entity2 .

title: Paraneoplastic autoimmune @entity14 with XXXX defined by @entity15 -IgG.

answer: @entity11


abstract: Autoantibodies have defined two paraneoplastic @entity4 related to @entity3 : @entity8 ("CAR"-IgG [23kDa, @entity16 ]) and @entity14 collapsin response-mediated protein 5 ( @entity15 -IgG [62kDa]). Among 16 @entity0 with @entity15 -IgG and @entity14 (aged 52-74 years; all smokers, 9 @entity0 ), we documented coexisting @entity11 in 5. None had CAR-IgG. Fifteen had subacute @entity9 , swollen optic discs, and field defects. Vascular leakage was evident at and remote from the disc; 5/5 tested had abnormal electroretinograms. Nine had striking vitreous cells. Vitrectomy showed @entity13 (4/4), predominantly @entity5 (+) (1/1). Most @entity0 had multifocal neurological accompaniments. Cerebrospinal fluid contained lymphocytes (7-32), elevated protein, multiple oligoclonal immunoglobulin bands, and @entity15 -IgG. Three @entity0 superficially resembled @entity10 at presentation. One autopsied @entity0 had predominantly @entity6 (+) T lymphocytes infiltrating optic nerve and spinal cord. Eleven @entity0 had confirmed @entity12 ; 1 had imaging evidence of @entity1 ; 3 had @entity7 . Full-length @entity15 protein was identified in normal retina and optic nerve by Western blot analyses. Photoreceptor cells, retinal ganglion cells, and nerve fibers exhibited @entity15 -specific immunoreactivity. In summary, @entity15 -IgG defines a paraneoplastic ophthalmological entity of combined @entity14 and @entity11 with vitreous inflammatory cells. Positive serology obviates the need for vitreous biopsy and expedites the search for @entity2 .

title: Paraneoplastic autoimmune XXXX with @entity11 defined by @entity15 -IgG.

answer: @entity14


abstract: Autoantibodies have defined two paraneoplastic @entity4 related to @entity3 : @entity8 ("CAR"-IgG [23kDa, @entity16 ]) and @entity14 collapsin response-mediated protein 5 ( @entity15 -IgG [62kDa]). Among 16 @entity0 with @entity15 -IgG and @entity14 (aged 52-74 years; all smokers, 9 @entity0 ), we documented coexisting @entity11 in 5. None had CAR-IgG. Fifteen had subacute @entity9 , swollen optic discs, and field defects. Vascular leakage was evident at and remote from the disc; 5/5 tested had abnormal electroretinograms. Nine had striking vitreous cells. Vitrectomy showed @entity13 (4/4), predominantly @entity5 (+) (1/1). Most @entity0 had multifocal neurological accompaniments. Cerebrospinal fluid contained lymphocytes (7-32), elevated protein, multiple oligoclonal immunoglobulin bands, and @entity15 -IgG. Three @entity0 superficially resembled @entity10 at presentation. One autopsied @entity0 had predominantly @entity6 (+) T lymphocytes infiltrating optic nerve and spinal cord. Eleven @entity0 had confirmed @entity12 ; 1 had imaging evidence of @entity1 ; 3 had @entity7 . Full-length @entity15 protein was identified in normal retina and optic nerve by Western blot analyses. Photoreceptor cells, retinal ganglion cells, and nerve fibers exhibited @entity15 -specific immunoreactivity. In summary, @entity15 -IgG defines a paraneoplastic ophthalmological entity of combined @entity14 and @entity11 with vitreous inflammatory cells. Positive serology obviates the need for vitreous biopsy and expedites the search for @entity2 .

title: Paraneoplastic autoimmune @entity14 with @entity11 defined by XXXX -IgG.

answer: @entity15


abstract: BACKGROUND: Secondary prevention studies for @entity1 show a remarkable variability in @entity1 recurrence rates. Various reports have raised questions regarding differences in baseline clinical characteristics and in methodology to explain this wide variability. HYPOTHESIS: The purpose of the present study is to examine the 2-year outcome after first @entity1 of atrial origin and to correlate secondary prognosis with left @entity4 . METHODS: Baseline evaluation included computed tomographic and/or magnetic resonance scanning, Doppler scanning, digital subtraction angiography, and transthoracic and transesophageal echocardiography to establish the diagnosis of @entity5 . Twenty-six @entity0 in nonrheumatic @entity4 and 13 in sinus rhythm were followed for recurrent @entity1 as endpoints (event +/-). RESULTS: @entity0 in sinus rhythm had a total of 23% (standard deviation +/- 12%) recurrence rate. All event (+) @entity0 were on @entity2 and died from this second @entity1 . Of @entity0 in nonrheumatic @entity4 , 50% were event (+) at the end of the first year ( @entity3 rate 46%). @entity0 on @entity6 therapy had 20% recurrence rate versus 70% on @entity2 (relative risk 0, 18, 95% confidence interval, 0.05-0.48, p 0.041). Inward peak velocity of left @entity4 was the only echocardiographic variable significantly reduced in event (+) @entity0 (21 +/- 7 vs. 31 +/- 17 cm/s, p 0.048). CONCLUSIONS: @entity0 with nonrheumatic @entity4 and first @entity1 are at increased risk for recurrence if severe dysfunction of the left @entity4 is present and if they do not receive @entity6 treatment. @entity0 with sinus rhythm and first @entity1 form a small @entity1 subgroup, in which recurrences are accompanied by a remarkably high @entity3 rate.

title: Secondary prognosis after XXXX of atrial origin: the role of left @entity4 .

answer: @entity1


abstract: BACKGROUND: Secondary prevention studies for @entity1 show a remarkable variability in @entity1 recurrence rates. Various reports have raised questions regarding differences in baseline clinical characteristics and in methodology to explain this wide variability. HYPOTHESIS: The purpose of the present study is to examine the 2-year outcome after first @entity1 of atrial origin and to correlate secondary prognosis with left @entity4 . METHODS: Baseline evaluation included computed tomographic and/or magnetic resonance scanning, Doppler scanning, digital subtraction angiography, and transthoracic and transesophageal echocardiography to establish the diagnosis of @entity5 . Twenty-six @entity0 in nonrheumatic @entity4 and 13 in sinus rhythm were followed for recurrent @entity1 as endpoints (event +/-). RESULTS: @entity0 in sinus rhythm had a total of 23% (standard deviation +/- 12%) recurrence rate. All event (+) @entity0 were on @entity2 and died from this second @entity1 . Of @entity0 in nonrheumatic @entity4 , 50% were event (+) at the end of the first year ( @entity3 rate 46%). @entity0 on @entity6 therapy had 20% recurrence rate versus 70% on @entity2 (relative risk 0, 18, 95% confidence interval, 0.05-0.48, p 0.041). Inward peak velocity of left @entity4 was the only echocardiographic variable significantly reduced in event (+) @entity0 (21 +/- 7 vs. 31 +/- 17 cm/s, p 0.048). CONCLUSIONS: @entity0 with nonrheumatic @entity4 and first @entity1 are at increased risk for recurrence if severe dysfunction of the left @entity4 is present and if they do not receive @entity6 treatment. @entity0 with sinus rhythm and first @entity1 form a small @entity1 subgroup, in which recurrences are accompanied by a remarkably high @entity3 rate.

title: Secondary prognosis after @entity1 of atrial origin: the role of left XXXX .

answer: @entity4


abstract: In a randomized controlled study, the efficacy of MCNU was compared with that of @entity3 in 95 @entity0 with @entity2 . Of the @entity0 studied, 95 were entered among whom 77 were evaluable. These comprised 40 for an MCNU group (M) and 37 for a @entity3 group (B). No significant difference was found statistically between the two groups with regard to background factors, i.e., male-to-female ratio, age, white blood cell counts, platelet counts, @entity1 or @entity4 chromosome. RESULTS: CR rate was 83% for M and 68% for B, and the number of days to CR was 88 for M and 155 for B. Blastic crisis was noted in 31% of M @entity0 and 33% of B @entity0 and the number of days to blastic crisis was 542.6 and 581.9, respectively for the two groups. Deaths accounted for 28% and 29% for each of M and B. Side effects were observed in 31% of M cases and 15% of B cases. A significant difference was observed only in the period to CR. MCNU showed almost equal efficacy to that of @entity3 but was superior to @entity3 in @entity0 who required rapid response. Side effects were mild and transient. Despite its delivery by intravenous injection, the administration of MCNU is deemed convenient, considering the long interval possible between treatments, being comparable in this respect with oral @entity3 . MCNU therefore seems a very effective drug for @entity2 .

title: [Randomized controlled study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in comparison with @entity3 for XXXX ].

answer: @entity2


abstract: In a randomized controlled study, the efficacy of MCNU was compared with that of @entity3 in 95 @entity0 with @entity2 . Of the @entity0 studied, 95 were entered among whom 77 were evaluable. These comprised 40 for an MCNU group (M) and 37 for a @entity3 group (B). No significant difference was found statistically between the two groups with regard to background factors, i.e., male-to-female ratio, age, white blood cell counts, platelet counts, @entity1 or @entity4 chromosome. RESULTS: CR rate was 83% for M and 68% for B, and the number of days to CR was 88 for M and 155 for B. Blastic crisis was noted in 31% of M @entity0 and 33% of B @entity0 and the number of days to blastic crisis was 542.6 and 581.9, respectively for the two groups. Deaths accounted for 28% and 29% for each of M and B. Side effects were observed in 31% of M cases and 15% of B cases. A significant difference was observed only in the period to CR. MCNU showed almost equal efficacy to that of @entity3 but was superior to @entity3 in @entity0 who required rapid response. Side effects were mild and transient. Despite its delivery by intravenous injection, the administration of MCNU is deemed convenient, considering the long interval possible between treatments, being comparable in this respect with oral @entity3 . MCNU therefore seems a very effective drug for @entity2 .

title: [Randomized controlled study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in comparison with XXXX for @entity2 ].

answer: @entity3


abstract: In intact neonatal piglets, two strains of enterotoxigenic @entity0 ( @entity2 ), which could adhere to epithelial cells and thus colonize the small intestine, attracted greater numbers of neutrophils into the lumen and wall of the intestine than did a nonenteropathogenic strain of @entity0 . Ligated loops of small intestine in 8-week-old @entity1 were used in attempts to identify the attributes of @entity2 involved in stimulating an increased enteroluminal migration of neutrophils. A nonenteropathogenic strain of @entity0 did not attract neutrophils into the intestinal lumen in this model. However, three of the five @entity2 strains tested did so. The three positive strains all produced heat-stable enterotoxin type b (STb). Neither of the negative @entity2 strains produced STb. An STb-containing culture supernatant prepared from a strain of @entity0 which contained an STb plasmid did not attract significantly more neutrophils than did a control supernatant prepared from the same strain of @entity0 without the plasmid. The @entity2 strains which attracted neutrophils in loops did not associate intimately with loop villi more consistently, nor did they grow to higher numbers in loops than strains which did not. It was concluded that there are increased numbers of neutrophils in the intestinal lumen during @entity2 infection of newborn @entity1 . However, attempts to identify the attribute(s) of @entity2 responsible for eliciting enteroluminal neutrophils were not successful.

title: Elicitation of enteroluminal neutrophils by enterotoxigenic and nonenterotoxigenic strains of XXXX in @entity1 .

answer: @entity0


abstract: In intact neonatal piglets, two strains of enterotoxigenic @entity0 ( @entity2 ), which could adhere to epithelial cells and thus colonize the small intestine, attracted greater numbers of neutrophils into the lumen and wall of the intestine than did a nonenteropathogenic strain of @entity0 . Ligated loops of small intestine in 8-week-old @entity1 were used in attempts to identify the attributes of @entity2 involved in stimulating an increased enteroluminal migration of neutrophils. A nonenteropathogenic strain of @entity0 did not attract neutrophils into the intestinal lumen in this model. However, three of the five @entity2 strains tested did so. The three positive strains all produced heat-stable enterotoxin type b (STb). Neither of the negative @entity2 strains produced STb. An STb-containing culture supernatant prepared from a strain of @entity0 which contained an STb plasmid did not attract significantly more neutrophils than did a control supernatant prepared from the same strain of @entity0 without the plasmid. The @entity2 strains which attracted neutrophils in loops did not associate intimately with loop villi more consistently, nor did they grow to higher numbers in loops than strains which did not. It was concluded that there are increased numbers of neutrophils in the intestinal lumen during @entity2 infection of newborn @entity1 . However, attempts to identify the attribute(s) of @entity2 responsible for eliciting enteroluminal neutrophils were not successful.

title: Elicitation of enteroluminal neutrophils by enterotoxigenic and nonenterotoxigenic strains of @entity0 in XXXX .

answer: @entity1


abstract: Methods for identifying Neisseria spp. include conventional and modified @entity0 degradation procedures, chromogenic enzyme substrate tests, and immunologic coagglutination tests for @entity2 . In this study, we evaluated the abilities of the RIM-N @entity0 degradation system (American MicroScan, Campbell, Calif.), the Gonochek II enzymatic identification system (Du Pont Co., Wilmington, Del.), and the Phadebact Gonococcus coagglutination test (Pharmacia Diagnostics, Piscataway, N.J.) to identify pathogenic Neisseria spp. and @entity3 . Both stock strains and clinical isolates, including 176 @entity2 , 173 @entity1 , 48 @entity4 , and 12 @entity3 strains, were tested. The RIM-N identified 98% of the gonococci, 99% of the meningococci, 94% of the @entity4 strains, and 100% of the @entity3 strains within 1 h. The Gonochek II system identified 99% of the gonococci, 97% of the meningococci, 100% of the @entity4 strains, and 100% of the @entity3 strains within 30 min. Phadebact coagglutination provided clearly positive results for only 77% of the @entity2 strains, producing negative or equivocal results with 23% of the strains. The RIM-N and Gonocheck II tests generally produced clear-cut reactions. An additional advantage of the Gonocheck II system was the small inoculum required for the performance of the test compared with the other systems, thus allowing the identification of @entity2 directly from the primary isolation medium.

title: Evaluation of the RIM-N, Gonochek II, and Phadebact systems for the identification of pathogenic Neisseria spp. and XXXX .

answer: @entity3


abstract: BACKGROUND: @entity3 carries the highest mortality rate of any @entity1 . Even the most critically ill anorexic @entity0 may present with normal 'standard' laboratory values, underscoring the need for a new sensitive biomarker. The complement cascade, a major component of innate immunity, represents a driving force in the pathophysiology of multiple inflammatory disorders. The role of @entity2 remains poorly understood. The present study was designed to evaluate the role of @entity5 levels, the extent of complement activation and of complement hemolytic activity in serum, as potential new biomarkers for the severity of @entity3 . @entity0 AND METHODS: This was a prospective cohort study on 14 @entity0 with severe @entity3 , as defined by a body mass index (BMI) <14 kg/m2. Serum samples were obtained in a biweekly manner until hospital discharge. A total of 17 healthy subjects with normal BMI values served as controls. The serum levels of @entity5 , @entity5 , @entity4 , sC5b-9, and of the 50% hemolytic complement activity (CH50) were quantified and correlated with the BMIs of @entity0 and control subjects. RESULTS: Serum C3 levels were significantly lower in @entity0 with @entity3 than in controls (median 3.7 (interquartile range (IQR) 2.5-4.9) vs 11.4 (IQR 8.9-13.7, P <0.001). In contrast, complement activation fragments and CH50 levels were not significantly different between the two groups. There was a strong correlation between index C3 levels and BMI (Spearman correlation coefficient = 0.71, P <0.001). CONCLUSIONS: @entity5 serum levels may represent a sensitive new biomarker for monitoring the severity of @entity3 . The finding from this preliminary pilot study will require further investigation in future prospective large-scale multicenter trials.

title: @entity5 serum levels in XXXX : a potential biomarker for the severity of disease?

answer: @entity3


abstract: BACKGROUND: @entity3 carries the highest mortality rate of any @entity1 . Even the most critically ill anorexic @entity0 may present with normal 'standard' laboratory values, underscoring the need for a new sensitive biomarker. The complement cascade, a major component of innate immunity, represents a driving force in the pathophysiology of multiple inflammatory disorders. The role of @entity2 remains poorly understood. The present study was designed to evaluate the role of @entity5 levels, the extent of complement activation and of complement hemolytic activity in serum, as potential new biomarkers for the severity of @entity3 . @entity0 AND METHODS: This was a prospective cohort study on 14 @entity0 with severe @entity3 , as defined by a body mass index (BMI) <14 kg/m2. Serum samples were obtained in a biweekly manner until hospital discharge. A total of 17 healthy subjects with normal BMI values served as controls. The serum levels of @entity5 , @entity5 , @entity4 , sC5b-9, and of the 50% hemolytic complement activity (CH50) were quantified and correlated with the BMIs of @entity0 and control subjects. RESULTS: Serum C3 levels were significantly lower in @entity0 with @entity3 than in controls (median 3.7 (interquartile range (IQR) 2.5-4.9) vs 11.4 (IQR 8.9-13.7, P <0.001). In contrast, complement activation fragments and CH50 levels were not significantly different between the two groups. There was a strong correlation between index C3 levels and BMI (Spearman correlation coefficient = 0.71, P <0.001). CONCLUSIONS: @entity5 serum levels may represent a sensitive new biomarker for monitoring the severity of @entity3 . The finding from this preliminary pilot study will require further investigation in future prospective large-scale multicenter trials.

title: XXXX serum levels in @entity3 : a potential biomarker for the severity of disease?

answer: @entity5


abstract: The present study was designed for exploration of hormonal disturbances underlying common forms of @entity7 . @entity9 ( @entity9 ) @entity0 and @entity1 amenorrheic subjects had significantly elevated @entity6 (E1) levels, elevated luteinizing hormone/follicle-stimulating hormone ratios, and an exaggerated luteinizing hormone response to luteinizing hormone-releasing hormone. However, @entity8 (delta 4A), the precursor of E1, was elevated only in @entity9 . Thus, the E1/delta 4A ratio, which provides an indirect index of aromatase activity in extraglandular sites, was raised in @entity1 subjects as a group but not in @entity9 subjects. These findings suggest that elevated E1 levels, which give rise to abnormal gonadotropin secretion, arise from increased available @entity10 in @entity9 but from an increased effect of aromatase (present in adipose tissue) in @entity1 subjects. Measurement of @entity10 and the E1/delta 4A ratio provides insights into the relative contributions of @entity9 and enhanced aromatase activity to the genesis of @entity7 in these groups. In @entity0 with suppressed @entity3 levels associated with @entity11 or @entity4 , follicle-stimulating hormone levels were suppressed, while luteinizing hormone was not elevated. Prolactin excess explains these findings in @entity11 . Plasma E1 levels and the E1/delta 4A ratio were suppressed in @entity0 with @entity4 , possibly as a consequence of reduced @entity5 . This finding suggests that hypothesis that a minimum level of E1, dependent upon adequate @entity5 , is critical for the normal mature function of the @entity2 . Abnormal E1/delta 4A ratios, high in @entity1 -associated @entity7 and suppressed in @entity4 -associated @entity7 , may provide specific markers for these groups of @entity0 .

title: Altered @entity8 and @entity6 dynamics associated with abnormal hormonal profiles in amenorrheic subjects with XXXX or @entity1 .

answer: @entity4


abstract: The present study was designed for exploration of hormonal disturbances underlying common forms of @entity7 . @entity9 ( @entity9 ) @entity0 and @entity1 amenorrheic subjects had significantly elevated @entity6 (E1) levels, elevated luteinizing hormone/follicle-stimulating hormone ratios, and an exaggerated luteinizing hormone response to luteinizing hormone-releasing hormone. However, @entity8 (delta 4A), the precursor of E1, was elevated only in @entity9 . Thus, the E1/delta 4A ratio, which provides an indirect index of aromatase activity in extraglandular sites, was raised in @entity1 subjects as a group but not in @entity9 subjects. These findings suggest that elevated E1 levels, which give rise to abnormal gonadotropin secretion, arise from increased available @entity10 in @entity9 but from an increased effect of aromatase (present in adipose tissue) in @entity1 subjects. Measurement of @entity10 and the E1/delta 4A ratio provides insights into the relative contributions of @entity9 and enhanced aromatase activity to the genesis of @entity7 in these groups. In @entity0 with suppressed @entity3 levels associated with @entity11 or @entity4 , follicle-stimulating hormone levels were suppressed, while luteinizing hormone was not elevated. Prolactin excess explains these findings in @entity11 . Plasma E1 levels and the E1/delta 4A ratio were suppressed in @entity0 with @entity4 , possibly as a consequence of reduced @entity5 . This finding suggests that hypothesis that a minimum level of E1, dependent upon adequate @entity5 , is critical for the normal mature function of the @entity2 . Abnormal E1/delta 4A ratios, high in @entity1 -associated @entity7 and suppressed in @entity4 -associated @entity7 , may provide specific markers for these groups of @entity0 .

title: Altered @entity8 and @entity6 dynamics associated with abnormal hormonal profiles in amenorrheic subjects with @entity4 or XXXX .

answer: @entity1


abstract: The present study was designed for exploration of hormonal disturbances underlying common forms of @entity7 . @entity9 ( @entity9 ) @entity0 and @entity1 amenorrheic subjects had significantly elevated @entity6 (E1) levels, elevated luteinizing hormone/follicle-stimulating hormone ratios, and an exaggerated luteinizing hormone response to luteinizing hormone-releasing hormone. However, @entity8 (delta 4A), the precursor of E1, was elevated only in @entity9 . Thus, the E1/delta 4A ratio, which provides an indirect index of aromatase activity in extraglandular sites, was raised in @entity1 subjects as a group but not in @entity9 subjects. These findings suggest that elevated E1 levels, which give rise to abnormal gonadotropin secretion, arise from increased available @entity10 in @entity9 but from an increased effect of aromatase (present in adipose tissue) in @entity1 subjects. Measurement of @entity10 and the E1/delta 4A ratio provides insights into the relative contributions of @entity9 and enhanced aromatase activity to the genesis of @entity7 in these groups. In @entity0 with suppressed @entity3 levels associated with @entity11 or @entity4 , follicle-stimulating hormone levels were suppressed, while luteinizing hormone was not elevated. Prolactin excess explains these findings in @entity11 . Plasma E1 levels and the E1/delta 4A ratio were suppressed in @entity0 with @entity4 , possibly as a consequence of reduced @entity5 . This finding suggests that hypothesis that a minimum level of E1, dependent upon adequate @entity5 , is critical for the normal mature function of the @entity2 . Abnormal E1/delta 4A ratios, high in @entity1 -associated @entity7 and suppressed in @entity4 -associated @entity7 , may provide specific markers for these groups of @entity0 .

title: Altered XXXX and @entity6 dynamics associated with abnormal hormonal profiles in amenorrheic subjects with @entity4 or @entity1 .

answer: @entity8


abstract: The present study was designed for exploration of hormonal disturbances underlying common forms of @entity7 . @entity9 ( @entity9 ) @entity0 and @entity1 amenorrheic subjects had significantly elevated @entity6 (E1) levels, elevated luteinizing hormone/follicle-stimulating hormone ratios, and an exaggerated luteinizing hormone response to luteinizing hormone-releasing hormone. However, @entity8 (delta 4A), the precursor of E1, was elevated only in @entity9 . Thus, the E1/delta 4A ratio, which provides an indirect index of aromatase activity in extraglandular sites, was raised in @entity1 subjects as a group but not in @entity9 subjects. These findings suggest that elevated E1 levels, which give rise to abnormal gonadotropin secretion, arise from increased available @entity10 in @entity9 but from an increased effect of aromatase (present in adipose tissue) in @entity1 subjects. Measurement of @entity10 and the E1/delta 4A ratio provides insights into the relative contributions of @entity9 and enhanced aromatase activity to the genesis of @entity7 in these groups. In @entity0 with suppressed @entity3 levels associated with @entity11 or @entity4 , follicle-stimulating hormone levels were suppressed, while luteinizing hormone was not elevated. Prolactin excess explains these findings in @entity11 . Plasma E1 levels and the E1/delta 4A ratio were suppressed in @entity0 with @entity4 , possibly as a consequence of reduced @entity5 . This finding suggests that hypothesis that a minimum level of E1, dependent upon adequate @entity5 , is critical for the normal mature function of the @entity2 . Abnormal E1/delta 4A ratios, high in @entity1 -associated @entity7 and suppressed in @entity4 -associated @entity7 , may provide specific markers for these groups of @entity0 .

title: Altered @entity8 and XXXX dynamics associated with abnormal hormonal profiles in amenorrheic subjects with @entity4 or @entity1 .

answer: @entity6


abstract: BACKGROUND: Readmission rates after pancreaticoduodenectomy (PD) for @entity1 have a significant impact on survival rate. Identification of risk factors for readmission may improve discharge plans and postoperative care. Data exist on the morbidity and mortality of @entity0 undergoing PD, but there are few reports about hospital readmissions after this procedure. Our aims were to evaluate the proportion and reasons for readmissions after PD for @entity1 , the factors influencing readmissions, and to analyze the relationship between readmission rate and survival rate. METHODS: Four hundred and thirty-six @entity0 , who had undergone PD for @entity1 in our centre from October 1999 to October 2009, a 10-year period, excluding perioperative (30-day) mortality, were identified. All readmissions within 1 year following PD were analyzed with respect to timing, location, reasons for readmission and outcome. We reviewed the hospitalization and readmissions for @entity0 undergoing PD, and compared @entity0 requiring readmission to @entity0 that did not require readmission. RESULTS: One hundred and forty-five @entity0 (33.26%) were readmitted within 1 year following PD, for further treatment or complications. In those cases, diagnoses associated with high rates of readmission included radiation and/or chemotherapy (48.96%), progression of disease (11.72%), @entity3 (11.72%), @entity4 /obstruction (6.20%), surgery-related complications (2.76%) and @entity2 (4.14%). The proportion of T4 in readmission group was lower than no readmission group (P < 0.05). The proportion of node positive cases in readmission group was much higher than no readmission group (P < 0.01). The number of readmission for complications reduced gradually in the first three months, and reached a second peak in the sixth and seventh month. Median survival was lower for the readmission group compared with the no readmission group (21 versus 46 months, P = 0.024). CONCLUSION: These results may assist in both anticipating and facilitating postoperative care as well as managing @entity0 expectations.

title: Multivariable analysis of factors associated with hospital readmission following pancreaticoduodenectomy for XXXX .

answer: @entity1


abstract: OBJECTIVES/HYPOTHESIS: Timing for repair of mandible @entity1 is a significant factor with regard to the rate of complication. STUDY DESIGN: Retrospective chart review of the previous 5 years (January 2005-January 2010). METHODS: All @entity0 undergoing mandible fracture fixation performed in the study period and having complete records were analyzed (n = 83). @entity0 were stratified by time to fixation following initial injury. Subjects were then separated by the presence or absence of any of the following complications: @entity2 , malunion, and nonunion. Logistical regression was then performed. RESULTS: Out of 83 @entity0 there were 4 @entity0 with six complications including malunion (n = 4) and @entity2 (n = 2). There were no cases of nonunion. Delay in surgical intervention did not influence the complication rate. CONCLUSIONS: Complications from repair of mandible @entity1 are rare; it is difficult to detect significant variables that may impact outcomes. We found no relationship between complications and timing to repair.

title: Timing for repair of mandible XXXX .

answer: @entity1


abstract: BACKGROUND: Liver transplantation is the most effective treatment for @entity5 ; however, @entity1 after transplantation can seriously affect the @entity0 's health. The aim of this research was to investigate the diagnosis and treatment of @entity2 following liver transplantation. METHODS: Clinical data for 232 liver transplant @entity0 at risk of @entity2 were examined for the presence of fungus in the blood, fluid, sputum, urine and stools of @entity0 and by chest or abdominal CT scans. @entity0 diagnosed with a @entity2 were treated with @entity4 or, if this was not effective, @entity6 or @entity3 . Immunosuppressive therapy was also reviewed. RESULTS: Thirty-seven of 232 (15.9%) @entity0 were diagnosed with a @entity2 , which occurred 4 to 34 days post-transplantation. @entity7 were diagnosed in 23 cases (62.2%) and @entity1 in 12 cases (32.4%). Twenty-one cases were effectively treated with @entity4 , 11 cases with @entity6 , and two cases with @entity3 ; however, three cases were not effectively treated with any of the antifungal agents. Overall, treatment was effective in 91.9% of @entity0 . CONCLUSIONS: @entity2 has a significant influence on survival rate after liver transplantation. Imaging studies, and pathogenic and biopsy examinations can diagnose @entity2 , which can be effectively treated with antifungal agents such as @entity4 , @entity6 or @entity3 .

title: Diagnosis and treatment of XXXX after liver transplantation.

answer: @entity2